Form 4: MapLight CSO Awarded Equity, Options for Retention

MapLight Therapeutics' Chief Scientific Officer, James Woodruff Lillie, received an award of 7,730 restricted stock units and 31,395 employee stock options.

Summary

• Chief Scientific Officer James Woodruff Lillie was granted 7,730 Restricted Stock Units (RSUs) and 31,395 employee stock options on February 5, 2026.
• The RSUs represent a contingent right to receive one share of voting common stock each, with a transaction price of $0.
• The stock options have an exercise price of $15.7 per share and are set to expire on February 4, 2036.
• Following these transactions, Mr. Lillie beneficially owns 298,862 shares of voting common stock and 31,395 employee stock options.
• The RSU award vests 1/4th on January 1, 2027, and 1/16th on each subsequent April 1, July 1, October 1, and January 1 thereafter.
• The stock options vest 1/4th of the total shares on February 5, 2027, and 1/48th of the total shares each month thereafter on the same day of the month.
• All vesting is contingent upon Mr. Lillie's continued service through each vesting date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal for executive retention and alignment of interests, which is generally favorable for long-term company stability and performance.

Positives

• The equity grants align the Chief Scientific Officer's long-term interests with those of the shareholders.
• The multi-year vesting schedules for both RSUs and stock options serve as a strong incentive for the retention of a key executive.

Negatives

• The future conversion of RSUs and exercise of stock options will result in a minor dilution of existing shares, which is typical for executive compensation.

Future Outlook

The vesting schedules for both the restricted stock units and employee stock options extend several years into the future, indicating a strategic long-term incentive structure designed to retain the Chief Scientific Officer and align his performance with the company's sustained growth.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as RSUs and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate key scientific and executive talent. This aligns the interests of the Chief Scientific Officer with the long-term success and shareholder value creation of MapLight Therapeutics.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of these awards, with multi-year vesting schedules, is consistent with typical executive compensation packages in the biotech sector, similar to those seen at companies like Biogen or Gilead Sciences, which use long-term incentives to retain critical R&D leadership.
• The specific number of units and options would need to be benchmarked against peer companies of similar market capitalization and stage of development to assess their relative size within industry norms.

Related Party Transactions

• The RSU award and stock option grant to James Woodruff Lillie, the Chief Scientific Officer, constitute a related party transaction as it involves compensation to a company officer.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through the retention and incentivization of a key executive; minor potential for dilution from future share issuance.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives within the company.

Next Steps

• Continued service of the Chief Scientific Officer to meet vesting conditions for RSUs and stock options.
• Future vesting events for RSUs on January 1, April 1, July 1, and October 1 annually, starting January 1, 2027.
• Future monthly vesting events for stock options, starting February 5, 2027.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a key executive, which is a standard practice for retention and incentive alignment. It does not present new information that would significantly alter the investment thesis or warrant a change in current holdings, thus a 'hold' recommendation is appropriate.

Keywords

MapLight Therapeutics, MPLT, SEC filing, Form 4, insider transaction, restricted stock units, RSU, stock options, executive compensation, Chief Scientific Officer, equity award, vesting schedule